.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,759,059

« Back to Dashboard
Patent 6,759,059 protects ABSTRAL and is included in one NDA. There has been one Paragraph IV challenge on Abstral.

This patent has thirty-two patent family members in twenty-four countries.

Summary for Patent: 6,759,059

Title: Fentanyl composition for the treatment of acute pain
Abstract:A pharmaceutical composition for the treatment of acute pain by sublingual administration is described. The composition comprises an essentially water-free, ordered mixture of fentanyl or a pharmaceutically acceptable salt thereof in the form of microparticles which are adhered to the surface of carrier particles which are substantially larger than the particles of fentanyl, and are essentially water-soluble. In a preferred embodiment, the composition also contains a bioadhesion and/or mucoadhesion promoting agent. The invention also relates to the preparation of the composition, and to the use of the composition for the treatment of acute pain.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Uppsala, SE), Lennernas; Hans (Uppsala, SE), Lennernas; Bo (Uddevalla, SE), Hedner; Thomas (Gallsta, SE)
Assignee: Diabact AB (Uppsala, SE)
Application Number:09/787,887
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 2nd percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-001Jan 7, 2011RXNo6,759,059► subscribeY MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-002Jan 7, 2011RXNo6,759,059► subscribeY MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Sentynl Theraps Inc
ABSTRAL
fentanyl citrate
TABLET;SUBLINGUAL022510-003Jan 7, 2011RXNo6,759,059► subscribeY MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,759,059

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803239Sep 24, 1998
PCT Information
PCT FiledSeptember 24, 1999PCT Application Number:PCT/SE99/01688
PCT Publication Date:March 30, 2000PCT Publication Number: WO00/16751

International Patent Family for Patent: 6,759,059

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria247950► subscribe
Australia6492899► subscribe
Australia764473► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc